Azipramine, also known by the code TQ-86, is a tetracyclic antidepressant that was synthesized and tested in animals in 1976 but never reached the market.
- Screened in animal models as a candidate antidepressant in the 1970s
- Never progressed past animal pharmacology testing
- Never marketed or approved anywhere
Overview
A 1970s antidepressant candidate that stalled at the animal-testing stage and never went further.
Mechanism
Azipramine belongs to the tetracyclic antidepressant (TeCA) chemical class, structurally related to but distinct from tricyclic antidepressants. Detailed receptor-binding or reuptake-inhibition data has not been published; its classification as a tetracyclic antidepressant is based on chemical structure and animal behavioral screening rather than confirmed mechanism.
Safetyrisks and cautions, not medical advice
No human safety or tolerability data exists. Azipramine was assayed only in animal pharmacology studies in 1976 and was never advanced to clinical trials.
Subjective profileweighing the evidence above
Nothing here for anyone. It was screened in animals in 1976, never reached human trials and never reached market, so there is no efficacy or safety record at all. A footnote in tetracyclic antidepressant history rather than a compound to use.
Resources
This entry is here for reference.
Reviews
My notesprivate to this device
FAQ
What is Azipramine used for?
Nothing currently. It was a 1970s tetracyclic antidepressant candidate, tested only in animals, that never reached human trials or the market.
How does Azipramine work?
Its precise mechanism was never published. It is classified as a tetracyclic antidepressant based on chemical structure and animal screening results.
Is Azipramine well-researched?
No. Documentation is limited to its 1976 synthesis and animal pharmacology; no clinical research was ever conducted.
Limitations of the evidence
- No human safety data exists
Adverse effects
- Never progressed past animal pharmacology testing
- Never marketed or approved anywhere